SETTING: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. OBJECTIVE: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. DESIGN: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. RESULTS: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. CONCLUSION: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.
SETTING: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. OBJECTIVE: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. DESIGN: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. RESULTS: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. CONCLUSION: A majority of the MDR-TBpatients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.
Authors: Ali Akbar Velayati; Parissa Farnia; Mohadese Mozafari; Maryam Fatemeh Sheikholeslami; Mona Afraei Karahrudi; Payam Tabarsi; Sven Hoffner Journal: Am J Trop Med Hyg Date: 2013-11-04 Impact factor: 2.345
Authors: Taher Azimi; Mohammad Javad Nasiri; Samin Zamani; Ali Hashemi; Hossein Goudarzi; Abbas Ali Imani Fooladi; Mohammad Mehdi Feizabadi; Fatemeh Fallah Journal: J Clin Tuberc Other Mycobact Dis Date: 2018-01-31
Authors: Mohammad Reza Masjedi; Payam Tabarsi; Majid Marjani; Parvaneh Baghaei Shiva; Mahshid Nasehi; Mohammad Mehdi Gooya; Parisa Farnia; Ali Akbar Velayati Journal: Tanaffos Date: 2013
Authors: Rebecca C Harris; Louis Grandjean; Laura J Martin; Alexander J P Miller; Joseph-Egre N Nkang; Victoria Allen; Mishal S Khan; Katherine Fielding; David A J Moore Journal: BMC Infect Dis Date: 2016-05-04 Impact factor: 3.090